Study Evaluating PPM-204 In Subjects With Type 2 Diabetes
NCT ID: NCT00425919
Last Updated: 2007-12-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
500 participants
INTERVENTIONAL
2007-01-31
2007-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PPM-204
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects currently treated with diet and exercise alone and subjects receiving a single oral antidiabetic medication
* BMI \> 23 and \< 43
* For subjects currently treated with 1 antidiabetic medication: HbA1c is greater than or equal to 6.8% and less than or equal to 8.5%.
* For subjects not currently treated with antidiabetic medications: HbA1c is greater than or equal to 7.2% and less than or equal to 9.0%
Exclusion Criteria
* Subjects currently receiving 2 or more oral antidiabetic medications
* Subjects requiring systemic corticosteroids, unless treatment was discontinued at least 4 weeks before the screening visit
* Subjects receiving warfarin
* Subjects currently receiving thiazolidinediones, unless treatment was discontinued 8 weeks before the screening visit
* Significant diabetic complications (retinopathy, nephropathy, symptomatic neuropathy)
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Wyeth is now a wholly owned subsidiary of Pfizer
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Monitor
Role: STUDY_DIRECTOR
Wyeth is now a wholly owned subsidiary of Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Artesia, California, United States
Los Angeles, California, United States
Chipley, Florida, United States
Destin, Florida, United States
Marianna, Florida, United States
West Palm Beach, Florida, United States
Omaha, Nebraska, United States
New York, New York, United States
Austin, Texas, United States
Richmond, Virginia, United States
Tacoma, Washington, United States
Buenos Aires, , Argentina
Corrientes, , Argentina
La Plata, , Argentina
Mar Del Plata Pcia de Bs. As, , Argentina
Ramos Mejia, Pcia de Bs., , Argentina
Daws Park, South Australia, Australia
Keswick, South Australia, Australia
Box Hill, Victoria, Australia
Vila Clementino - Sao Paulo, , Brazil
Edmonton, Alberta, Canada
Toronto, Ontario, Canada
Charlottetown, Prince Edward Island, Canada
Laval, Quebec, Canada
Saint-Janvier, Quebec, Canada
Beijing, , China
Beijing, , China
Krapinske Toplice, , Croatia
Rijeka, , Croatia
Zagreb, , Croatia
Athens, , Greece
Thessaloniki, , Greece
Wan Chai, , Hong Kong
Bangalore, Karnataka, India
Kochi, Kerala, India
Pune, Maharashtra, India
Chennai, Tamil Nadu, India
Vellore, Tamil Nadu, India
Catanzaro, , Italy
Pisa, , Italy
Aguascalientes, , Mexico
Mexico City, , Mexico
Mexico City, , Mexico
Miguel Hidalgo, , Mexico
Monterrey N.L, , Mexico
Tlapan, , Mexico
Bucharest, , Romania
Bucharest, , Romania
Cluj-Napoca, , Romania
Moscow, , Russia
Moscow, , Russia
Moscow, , Russia
Moscow, , Russia
Saint Petersburg, , Russia
Saint Petersburg, , Russia
Belgrade, , Serbia and Montenegro
Port Elizabeth, Eastern Cape, South Africa
Benoni, Gauteng, South Africa
Pretoria, Gauteng, South Africa
Pretoria, Gauteng, South Africa
Temba, North West, South Africa
Kharkiv, , Ukraine
Kyiv, , Ukraine
Poltava, , Ukraine
Uzhhorod, , Ukraine
Dundee, , United Kingdom
Edinburgh, , United Kingdom
Livingston, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
3180A1-200
Identifier Type: -
Identifier Source: org_study_id